Correlation between PSA response and response assessment with 68Ga-PSMA-11 PET/CT-derived metabolic parameters in patients treated with 225Ac-PSMA-617 for metastatic prostate carcinoma
PSA decline ≥50% is the validated criteria for assessing response to treatment in patients with prostate carcinoma. 68Ga-PSMA-11 PET/CT-derived metabolic parameters such as SUVmax, SUVmean, whole-body tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA) are increasingly being reported as metrics for response assessment. We herein compare the response assessment using PSA decline versus 68Ga-PSMA-11 PET/CT-derived metabolic parameters in patients treated with 225Ac-PSMA-617 for metastatic castration-resistant prostate carcinoma (mCRPC).
LAWAL I;
MORGENSTERN Alfred;
KNOESEN Otto;
VORSTER Mariza;
POPOOLA Go;
MAHAPANE Johncy;
LENGANA T;
BOSHOMANE T;
MOKOALA K;
BRUCHERTSEIFER Frank;
SATHEKGE Mike;
2019-10-18
SPRINGER
JRC116618
1619-7070 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC116618,
10.1007/s00259-019-04486-2 (online),
Additional supporting files
| File name | Description | File type | |
|---|
